FIELD: pharmacology.
SUBSTANCE: quick-solving drug form of solid oral vaccine contains an immunogenic quantity of antigenic preparation and an agent forming an immune response potentiating matrix consisting of 2.0% of modified starch (m/v), 2.4% of mannitol (m/v) and 1.2% of gelatine (m/v). An immune response is induced when the drug form is administered to a patient by placing in the oral cavity.
EFFECT: effective stimulation of immunity against infection.
11 cl, 12 dwg, 4 tbl
| Title | Year | Author | Number |
|---|---|---|---|
| ORALLY DISPERSABLE VACCINE CONTAINING VIROSOMES | 2019 |
|
RU2808276C2 |
| ADJUVANT COMPOSITION CONTAINING POLY-GAMMA-GLUTAMIC ACID | 2005 |
|
RU2390352C2 |
| ALLERGEN-CONTAINING DOSAGE FORM | 2003 |
|
RU2372074C2 |
| LYOPHILIZED PHARMACEUTICAL COMPOSITIONS FOR VAGINAL DELIVERY | 2017 |
|
RU2753864C2 |
| METALLOPROTEINASE OLIGOPEPTIDES AND THEIR THERAPEUTIC USE | 2011 |
|
RU2680717C2 |
| OLIGOPEPTIDES OF METALLOPROTEINASE AND THERAPEUTIC USE THEREOF | 2011 |
|
RU2585388C2 |
| CHIRAL NUCLEIC ACID ADJUVANT | 2013 |
|
RU2677639C2 |
| STABLE IMMUNOGENIC COMPOSITION FOR ORAL ADMINISTRATION FOR INFECTIOUS DISEASE PROPHYLAXIS | 1992 |
|
RU2069567C1 |
| METALLOPROTEINASE-9 OLIGOPEPTIDES AND THEIR THERAPEUTIC USE | 2013 |
|
RU2628702C2 |
| IMMUNOGENIC COMPOSITIONS OF Bordetella bronchiseptica | 2012 |
|
RU2554480C2 |
